Electromed, Inc. ELMD
We take great care to ensure that the data presented and summarized in this overview for Electromed, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELMD
View all-
Vanguard Group Inc Valley Forge, PA367KShares$11.3 Million0.0% of portfolio
-
Punch & Associates Investment Management, Inc. Edina, MN360KShares$11.1 Million0.46% of portfolio
-
Dimensional Fund Advisors LP Austin, TX278KShares$8.57 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA214KShares$6.59 Million0.01% of portfolio
-
Mario Gabelli Gamco Investors, Inc. Et Al | Rye, Ny135KShares$4.16 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny123KShares$3.8 Million0.0% of portfolio
-
Hunter Associates Investment Management LLC Pittsburgh, PA102KShares$3.15 Million0.34% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX79.4KShares$2.44 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA67.9KShares$2.09 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL57.3KShares$1.76 Million0.0% of portfolio
Latest Institutional Activity in ELMD
Top Purchases
Top Sells
About ELMD
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care and institutional markets for patients with bronchiectasis, cystic fibrosis, and neuromuscular diseases. It markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Insider Transactions at ELMD
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 05
2024
|
Andrew Summers Director |
SELL
Open market or private sale
|
Indirect |
37,404
-2.89%
|
$1,047,312
$28.78 P/Share
|
Dec 04
2024
|
Andrew Summers Director |
SELL
Open market or private sale
|
Indirect |
12,731
-2.83%
|
$369,199
$29.98 P/Share
|
Dec 03
2024
|
Andrew Summers Director |
SELL
Open market or private sale
|
Indirect |
35,436
-7.25%
|
$1,063,080
$30.18 P/Share
|
Dec 02
2024
|
Andrew Summers Director |
SELL
Open market or private sale
|
Indirect |
17,463
-2.29%
|
$523,890
$30.32 P/Share
|
Dec 01
2024
|
Kathleen A Tune Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+20.0%
|
-
|
Dec 01
2024
|
Andrea M. Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+16.67%
|
-
|
Dec 01
2024
|
Gregory Fluet Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+14.29%
|
-
|
Dec 01
2024
|
Joseph L. Galatowitsch Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+20.0%
|
-
|
Dec 01
2024
|
Kathleen Skarvan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+5.14%
|
-
|
Dec 01
2024
|
Stan K. Erickson Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+7.73%
|
-
|
Dec 01
2024
|
Andrew Summers Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+25.0%
|
-
|
Nov 19
2024
|
Kathleen Skarvan Director |
SELL
Open market or private sale
|
Indirect |
56,945
-66.27%
|
$1,537,515
$27.97 P/Share
|
Nov 19
2024
|
Kathleen Skarvan Director |
SELL
Open market or private sale
|
Direct |
50,602
-49.13%
|
$1,366,254
$27.92 P/Share
|
Nov 18
2024
|
Kathleen Skarvan Director |
SELL
Open market or private sale
|
Direct |
42,453
-29.19%
|
$1,188,684
$28.16 P/Share
|
Sep 30
2024
|
James L. Cunniff CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
34,426
-30.36%
|
$722,946
$21.47 P/Share
|
Sep 30
2024
|
James L. Cunniff CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
87,500
+43.55%
|
-
|
Sep 03
2024
|
James L. Cunniff CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
15,900
+38.04%
|
-
|
Sep 03
2024
|
Bradley M. Nagel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+24.34%
|
-
|
Mar 01
2024
|
James L. Cunniff CEO and President |
BUY
Open market or private purchase
|
Direct |
9,000
+47.37%
|
$135,000
$15.25 P/Share
|
Dec 14
2023
|
Andrew Summers Director |
BUY
Open market or private purchase
|
Indirect |
28,797
+7.56%
|
$287,970
$10.5 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 42.4K shares |
---|---|
Open market or private purchase | 37.8K shares |
Exercise of conversion of derivative security | 87.5K shares |
Open market or private sale | 253K shares |
---|---|
Payment of exercise price or tax liability | 34.4K shares |